Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
aducanumab
Biotech
Completion of Lilly's Alzheimer's submission slips out of Q1
The timeline for completing an accelerated approval request for Eli Lilly’s Alzheimer’s treatment donanemab has slipped out of the first quarter.
Annalee Armstrong
Feb 3, 2022 10:19am
Eli Lilly CEO Ricks is ready to take on Biogen in Alzheimer's
Jan 20, 2022 9:00am
Sandrock retires as Biogen R&D chief amid Aduhelm fallout
Nov 16, 2021 5:13am
OIG plans 2023 review of FDA's accelerated pathway after Aduhelm
Aug 4, 2021 1:56pm
Lilly reveals 2 new analyses for Alzheimer's drug donanemab
Jul 29, 2021 4:25pm
Biogen to navigate an ethics minefield for post-approval trial
Jun 23, 2021 8:54am
